Type 1 Diabetes (T1D)
Conditions
Keywords
probiotics, genetics
Brief summary
While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.
Interventions
Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
DRUGPlacebo Capsule
Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
Sponsors
University of Florida
Juvenile Diabetes Research Foundation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
A randomized, double-blinded, placebo-controlled clinical trial will be carried out with children and adolescents (8-less than 18 years old) with T1D
Eligibility
Sex/Gender
ALL
Age
8 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* have confirmed T1D by physician diagnosis * have normal values at screening for complete blood count (CBC) and complete metabolic profiles (with the exception of fasting glucose and HbA1c) * are able to swallow a capsule * are willing to complete weekly online questionnaires * are willing to consume a probiotic * are willing to provide stool samples throughout the study * are willing to provide blood samples throughout the study * are willing to take three stimulated C-peptide tests * are able to access a computer with Internet throughout the study
Exclusion criteria
* being treated for any diseases or illnesses such as gastrointestinal disease (gastric ulcers, Crohn's disease, ulcerative colitis, etc.) * being treated for chronic kidney disease * have had or are currently being treated for other immune-compromising diseases or conditions (HIV, AIDS, hepatitis, cancer, leukemia, organ transplant, Lupus, DiGeorge syndrome, selective deficiency of Immunoglobulin A (IgA), Bruton's disease etc.) * have an underlying structural heart disease * currently live with an immunocompromised person * are currently taking medications for constipation and/or diarrhea * have taken antibiotics within the past 2 weeks prior to randomization * are currently taking a probiotic supplement and are unwilling to discontinue it a minimum of 2 weeks prior to the study start * are a current smoker * are currently pregnant or lactating or a female who plans to become pregnant in the next 6 months * have a known allergy to milk or milk protein.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety will be evaluated according to complete blood count (CBC) and complete comprehensive metabolic panel (CMP) | 52 weeks | CBC and CMP will be evaluated at four different time points during study: 1st measure will be at screening visit and before starting intervention (visit 1/week -4, baseline period), 2nd measure will be after 12 weeks after starting intervention (visit 2/ week 12), 3rd measure will be after the 24 weeks of intervention (visit 3/ week 24) and the 4th measure will be 24 weeks later, end of washout period (visit 4/week 48). Values should be within the normal values except for glucose. |
| Tolerance will be evaluated according to their responses on weekly questionnaires | 52 weeks | The weekly questionnaire will ask participants to respond to questions regarding their gastrointestinal health (bowel movement frequency, gastrointestinal and other symptoms (i.e., constipation, diarrhea, stomach pain) and general wellness (if you consumed an antibiotic, visited a doctor, etc.). The questionnaires follow a scale from 1-7, 1 = No discomfort at all, 7 = Very severe discomfort. |
| Adverse Event and/or Serious Adverse Event | 24 weeks | Adverse Event and/or Serious Adverse Event will be recorded daily by parents and notified to investigator within 24 hrs., in particular gastro-intestinal symptoms, fever and rashes. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMichael Haller
University of Florida
Outcome results
None listed